Dr. Mark Popovsky Receives Prominent Award for Leadership in Transfusion Medicine

October 26, 2009 8:30 AM EDT

BRAINTREE, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) announced today that Dr. Mark Popovsky, Vice President and Chief Medical Officer, has been awarded the Emily Cooley Memorial Award and Lectureship by AABB. The Memorial Award was founded as a lectureship in 1963 and is given annually to a person who has demonstrated teaching ability and made a major contribution to the fields of immunohematology, transfusion medicine, and cellular therapies.

"The Emily Cooley Memorial Award and Lectureship is an excellent recognition of Dr. Popovsky's dedication to and impact on the transfusion industry. We are honored to have Dr. Popovsky as part of our team and congratulate him on this award," said Brian Concannon, President and CEO of Haemonetics.

Dr. Popovsky joined Haemonetics in 2000 as Corporate Medical Director and President of the Cell Processing Division. In addition to his work at Haemonetics, he is currently an Associate Clinical Professor of Pathology at Harvard Medical School and Beth Israel Deaconess Medical Center. Dr. Popovsky currently serves on the editorial board of 5 journals. He has authored, or co-authored, over 375 publications in transfusion medicine and pathology. He is editor and co-editor of two reference books in transfusion medicine. In 2004, he served in Nigeria as a member of the U.S. President's Emergency Plan for AIDS Relief delegation to that country.

Prior to Haemonetics, Dr. Popovsky was with the American Red Cross, New England Region, where he held the positions of Medical Director and then Chief Executive Officer. He also served as Director of the Transfusion and Intravenous Services at the Mayo Clinic. Dr. Popovsky is an honors graduate of the University of Vermont, College of Medicine.

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

    Contact:
    Julie Fallon
    Tel. (781) 356-9517
    Alt. Tel. (617) 320-2401

SOURCE Haemonetics Corporation


Related Categories

Press Releases

Stocks Mentioned

HAE 54.33

-0.65 -1.18%
Volume: 77,704
Track HAE


Add Your Comment